- (-%)
Source:
We are a biopharmaceutical company driven by our purpose to solve major medical, societal and economic challenges in healthcare. We have a singular focus on one of the greatest global healthcare challenges and burdens - that presented by atherosclerotic cardiovascular disease, or ASCVD, which remains the number one cause of death in the United States and worldwide. We take on that challenge by developing inclisiran, the investigational RNA interference, or RNAi, therapeutic, that specifically inhibits production of proprotein convertase subtilisin/kexin type9,
Country | United States |
Headquarters | parsippany, new jersey |
Phone Number | 973-290-6000 |
Industry | manufacturing |
CEO | Clive A. Meanwell |
Website | http://www. |